Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Buloxibutid · C-21, M-24

Small molecule · developed by Vicore Pharma

Phase 3 Most advanced trial
VCRE Developer
2 Registered trials

What is Buloxibutid?

Buloxibutid (also known as C21 or Compound 21) is a drug studied in idiopathic pulmonary fibrosis and COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
C-21, M-24
Drug type
Small molecule
Therapy area
Infectious disease, Respiratory
Developer
Vicore Pharma AB (VCRE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
RC2V4W0EYC

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04880642 Phase 3 COVID-19 Completed VCRE
NCT06588686 Phase 2 Idiopathic Pulmonary Fibrosis (IPF) Active not recruiting VCRE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary Fibrosis (IPF)COVID-19

More from Vicore Pharma

Follow VCRE, the company behind Buloxibutid

See VCRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VCRE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.